Recent Articles

• 
  Pharmaceutical R&D

  HK inno.N’s GLP-1 Obesity Drug Outperforms Wegovy

  Conceptual diagram of the world’s first cyclic adenosine monophosphate (cyclic AMP, cAMP)-biased GLP-1 receptor agonist. By applying a selective signal transduction design (cAMP, right side of image), the drug is said to reduce side effects while enhancing weight loss. Provided by Sciwind Bioscience

  2026.06.09
• 
  Clinical Trial

  Daewoong Pharma Presents Enblo Glucose-Lowering Model at Europe Meeting

  Daewoong Pharmaceutical clinical researcher Yoon Seoyeon explains the integrated model-based study results for Enblo to visitors. Provided by Daewoong Pharmaceutical Daewoong Pharmaceutical announced on the 8th that it had presented research results analyzing the relationship between drug exposure a

  2026.06.08
• 
  Pharmaceutical R&D

  Korean Blood Cancer Drug Limcato Cuts Treatment Time

  “With the development of domestically produced CAR‑T (chimeric antigen receptor T‑cell) therapies, local manufacturing has become possible. Because CAR‑T is made by collecting the patient’s own immune cells, ‘T cells’, overseas therapies require about six weeks, but with domestic production this can

  2026.06.08
• 
  Clinical Trial

  Dementia Drug Candidate Shows Cognitive Gains Despite Missed Goal

  Choline alfoscerate product group. Results of a clinical re‑evaluation conducted to verify the efficacy of the prescription‑only active ingredient “choline alfoscerate,” which has been used to treat mild cognitive impairment and to improve brain function, have recently been released, drawing renewed

  2026.06.05
• 
  AI Healthcare

  SCL Healthcare Unveils Multi-Cancer Early Detection Tech at ASCO

  SCL Healthcare presented research results including multi-cancer early detection (MCED) at ASCO 2026. Getty Images Bank SCL Healthcare participated in the American Society of Clinical Oncology (ASCO 2026), one of the world’s largest oncology conferences, to showcase its clinical trial analysis servi

  2026.06.05
• 
  Drug Development

  MediPost Says FDA Approves Phase 3 Trial of Cartistem

  Medipost announced on the 4th that its stem cell therapy for osteoarthritis, “Cartistem,” has received approval from the U.S. Food and Drug Administration (FDA) to proceed with a single Phase 3 clinical trial for marketing authorization. Given that the FDA typically requires results from two or more

  2026.06.05
• 
  ADA 2026 / Drug Development

  Daewon Pharma Unveils Quadruple Obesity Drug at ADA

  Daewon Pharmaceutical Daewon Pharmaceutical will disclose preclinical data for a quadruple-action obesity treatment candidate at the American Diabetes Association. The candidate, which has demonstrated not only weight loss but also the potential to protect pancreatic beta cells and improve kidney fu

  2026.06.04
• 
  GSC 2026

  CGBio Unveils Spine Strategy: Robot Navigation, Bone Regeneration

  CGBio GSC 2026 endoscopic workshop site. Provided by Daewoong Group Daewoong Group affiliate CGBio and its subsidiary CGBio Medtech presented a spinal treatment strategy that combines robotic navigation, endoscopic surgery, and bone regeneration therapy at a global spine congress.Bioregenerative med

  2026.06.04
• 
  AI Chip

  Neuromorphic ‘Dream Chip’ Advances With Brain Science

  An image related to neuromorphic semiconductors from the paper “Neuromorphic electronics based on copying and pasting the brain” published in Nature Electronics in 2021. Provided by Samsung Electronics 20W versus 1,000W.This is the power gap between the human brain and Nvidia’s latest artificial int

  2026.06.04
• 
  Pharmaceutical R&D

  Hanmi Exports KRW 1.9 Trillion Biologic Drug Tech to Lilly

  Hanmi Pharmaceutical headquarters building. News1 Hanmi Pharmaceutical has signed a major technology export agreement with U.S. pharmaceutical company Eli Lilly to transfer the rights to its bio-new drug candidate “sonepegletide.” On the 1st, Hanmi Pharmaceutical announced that it had signed a licen

  2026.06.02